Mineralys Therapeutics Inc (MLYS)

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a...

Form 8-K - Current report

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

– Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to...

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful...

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

RADNOR, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a...

Form 8-K - Current report

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

– NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22...

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a...

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a...

Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

RADNOR, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a...